Results from a controlled clinical trial from China on the use of hydroxychloroquine as a treatment for Covid-19 have shown no significant differences in health outcomes between the control group and patients who received the experimental drug. 

Thirty patients hospitalized for Covid-19 participated in the trial. Fifteen were treated with 400mg of chloroquine for five days and fifteen received the standard supportive care. On Day 7 of the trial both groups were evaluated.

The results:

CT scans showed there was little difference in the progression of the disease for those given the hydroxychloroquine treatment and those who received conventional care.

Read full article on Forbes

Originally published on Forbes (March 25, 2020)